lumbrokinase- anyone ever try it

[Guest guest]

looking to hear from anyone taking lumbrokinase. considering taking it

want to

know side effects

 

thnks

 

Barry

[Guest guest]

Hi Barry, & All,

 

> looking to hear from anyone taking lumbrokinase. considering taking it

> want to know side effects thnks Barry

 

I have no experience of it, but searched Google. See:

http://www.digitalnaturopath.com/treat/T447441.html

 

www.nutrimedical.com/products.jhtml?method=view & product.id=1303

says:

 

Lumbrokinase ( Boluoke order for US Delivery) Clot and Plaque Blocker

60 c 60 capsules 20 mg $92.77

 

Ingredients: Lumbrokinase is an earthworm extract that inhibits

plaminogen activator one, lowers fibrinogen levels, and reduces

probability of clot and plaque formation.

 

Cautions/Warnings: You must be seen by your medical doctor, and

monitored especially if on coumadin and other anticoagulants such as

Plavix, the platelet drugs.

 

Adverse Reactions: People with known allergies to earthworm should

not take lumbrokinase. Those who have had recent surgery, trauma,

bleeding disorders, ulcers, or who have suffered aneurysms should not

take lumbrokinase without physician supervision. Patients should stop

Lumbrokinase one week prior to surgery, and should be able to resume

use 15 days after surgery or at physicianfs discretion.

 

Contraindicaitons: Lumbrokinase has been safely used together with

blood thinners like Aspirin, Heparin or Coumadin and does not have

adverse drug-drug interactions nor increase the chance of bleeding

other than what is inherent to the blood thinners.

 

Do not take Lumbrokinase with enzyme products, as they may nullify the

effectiveness of Lumbrokinase. Lumbrokinase is not recommended for

use by pregnant or lactating women as safety information for this

population is not yet complete.

 

Common Uses: Lumbrokinase optimizes circulatory health by utilizing

earthworm derived enzymes that promote healthy fibrinolytic activity,

platelet coagulation functions and blood viscosity.

 

Lumbrokinase enhances the delivery of oxygen and nutrients to sites of

injury or illness throughout the body to promote optimal health of tissue.

 

Lumbrokinase has extensive clinical use in China since 1995, and has

an excellent safety record. Published Research Studies: In a Chinese

study conducted at Beijing Tongren Hospital, patients with

hyperfibrinogenemia were orally administered six tablets of

lumbrokinase per day for three weeks. Serum fibrinogen levels were

examined before and after treatment. In comparison with the control

groups given antilipemia or antiplatelet aggregation drugs, serum

fibrinogen in the lumbrokinase treated group significantly decreased two

weeks after treatment in a time related manner [before treatment (5.34

} 0.48) g/L, two weeks after treatment (4.33 } 1.09) g/L, three weeks

after treatment (3.71 } 0.48) g/L]. These results showed lumbrokinase

could relieve hyperfibrinogenemia, and that the formation of thrombi

would be decreased.

 

Lumbrokinase had fewer side effects and was considered as a potential

preventive drug for coronary atherogenesis disease. Additional research

investigated the effect of lumbrokinase on antiocoagulation and

fibrinolysis in treating cerebral infarction2. Patients were randomly

divided into the lumbrokinase treatment group (n=31) or a control group

(n=20). The single blind method was used in this investigation and the

Chinese stroke score was used to evaluate the results of treatment

before and after administration of lumbrokinase. Kaolin partial

thromboplastin time (KPTT), prothrombin time (PT), fibrinogen content,

and vWF content were analyzed, while tissue plasminogen activator (t-

PA) activity, plasminogen activator inhibitor (PAI) activity, D-dimer level

were assayed. In both groups the stroke score decreased after

administration, but in the treatment group, it was more obvious. In the

treatment group KPTT was prolonged, t-PA activity and D-dimer level

increased, while the content of fibrionogen decreased significantly.

There were no significant changes of PT and PAI activity in both groups.

 

The researchers concluded that lumbrokinase is beneficial to the

treatment of cerebral infarction and the effect of lumbrokinase is related

to the inhibition of intrinsic coagulation pathway and the activation of

fibrinolysis via an increase of t-PA activity.

 

Comparison Of Boluoke With Other Enzymes

 

FAQ: Lumbrokinase Frequently Asked Questions

 

1. How long before surgery should patient stop taking Lumbrokinase?

Patient should stop Lumbrokinase 1 week prior to surgery, and should

be able to resume taking lumbrokinase 15 days after surgery or at the

physicianfs discretion.

 

2. Can lumbrokinase be safely used together with other blood thinners?

Lumbrokinase had been safely used together with blood thinners like

Aspirin, Heparin or Coumadin in various clinical studies, and does not

have adverse drug-drug interactions nor increase the chance of

bleeding other than what is inherent to the blood thinners. In a 1989

study Park et al. gave lumbrokinase to 10 normal volunteers, 10 DVT

patients on warfarin, and 5 patients with essential hypertension. No

change in PT, APTT was observed during the course of treatment, and

there was no hemorrhagic complication.

 

3. Has there been any study comparing lumbrokinase and other blood

thinners? Lumbrokinase has been put head-to-head with ticlopidine

(Ticlid) in a clinical trial treating patients with angina pectoris, and the

results showed that lumbrokinase is as effective as ticlopidine in

reducing symptoms and improving EKG readings.

 

4. Can Lumbrokinase be used on pregnant women? There is currently

no clinical study using lumbrokinase on pregnant women, even though

teratogenicity studies on animals showed no effect on pregnancy

weight, fetal growth, abortion rate, still birth rate, and fetal resorption

rate in mice compared to the placebo group. There was also no birth

defect detected. However, pregnant patients should only use

Lumbrokinase under physicianfs approval and guidance.

 

5. How fast and how much can Lumbrokinase lower the patientfs

plasma fibrinogen level? The rate would vary depending on the

condition being treated and the starting fibrinogen level. Some studies

showed a reduction of 21% in 12 weeks, and some showed a reduction

rate of 33% in 21 days. Most trials showed a reduction rate that is in

between. On average, a reduction rate of 10-20% (or more) in 4 weeks

can be expected when patients are on the full dosage of 2 capsules

three times daily. Boluok®e will not reduce plasma fibrinogen level to

below normal.

 

6. What is lumbrokinasefs effect on FDP (Fibrin Degradation Product)

or D-Dimer? FDP and D-Dimer levels have been shown to increase

sharply within three days of lumbrokinase administration in healthy and

hyperfibrinosis individuals.

 

7. Does Lumbrokinase affect ESR or C-RP? There are studies showing

that lumbrokinase can significantly decrease ESR, C-RP, and TXB2.

 

8. What are the contra-indications for taking Lumbrokinase? Contra-

indications for Lumbrokinase are: allergy to lumbrokinase or earthworm;

recent surgery, lumbar puncture, or arterial puncture; trauma;

aneurysm; active internal bleeding or GI ulceration; or any other

bleeding disorders.

 

9. Is Lumbrokinase effective in treating atherosclerosis? There is

currently no data on lumbrokinase effect on atherosclerotic plaques.

Because arterial plaques consist of cholesterol, minerals, cells and

other substances beside fibrin, and lumbrokinase may not be able to

reduce them on its own. Lumbrokinase is more likely to prevent plaque

formation or re-formation in combination with chelation treatment. There

is, however, evidence showing that lumbrokinase has a synergistic

effect when combined with antibiotics in the killing of bacteria with a

protective bio-film (e.g. nanobacteria, pseudomonas). Even though it is

still controversial, some researchers believe that nanobacteria play a

central role in the atherosclerotic process

 

10. Can Lumbrokinase be combined with other enzyme products?

There is a theoretical possibility that Lumbrokinase may be cleaved and

rendered ineffective by other enzymes, so we currently do not

recommend dosing Lumbrokinase with another enzyme product. If you

do have to take other enzyme products while on Lumbrokinase, try to

space more time between the dosing of the two enzyme products (i.e. at

least 2 hours).

 

11. What is the suggested protocol for starting Lumbrokinase? If

Lumbrokinase is to be used as a treatment in chronic illnesses, it should

be taken at the dose of 2 capsules three times daily 30 minutes before

meals for 3 to 6 weeks, then at the dose of 1 capsule three times daily

for maintenance.,

 

1. Ying, G., Mingzhao, Q. gLumbrokinase in Treatment o fPatients

with Hyperfibrinogenemia of Coronary Atherogenesis Disease.h

Capital University of Medical Sciences Report, 1999; 4 (20).

 

2. Jin, L., Jin, H., Zhang, G., Xu, G. gChanges in coagulation and

tissue plasminogen activator after the treatment of cerebral infarction

with lumbrokinase.h Clin Hemorheol Microcirc. 2000 23:213-8.

 

Product Name Boluoke Nattokinase

 

Boluoke Imitators Serrapeptidase Bromelain

 

Packaging 60 capsule 90 capsules mostly 30 to 36 capsules 60-90

tablets quite variable

 

Main Ingredient(s) 20mg lumbrokinase per cap 38mg nattokinase per

cap mostly 200mg to 250mg of lumbrokinase or lumbrokinase/ herbs

mixture per cap 5 or 10mg of serrapeptidase per cap usually 500mg of

bromelain per cap, but varies greatly between companies

 

Enteric coated Yes Yes Yes Yes No

Dosage 1 cap one to three times daily for prevention; 2 caps three times

daily for active treatment 2 caps three times daily 4 capsules daily; or 6

to 9 capsules daily 10mg three times daily 750-2000mg per day usually,

or higher

 

Source of enzymes Earthworms Natto cheese Earthworm Silkworm

Pineapple & its stems

 

Historical usage of enzyme source with a safe record Yes, in Traditional

for a few thousand years Yes, in traditional Japanese

diet as Natto for over a thousand years Yes, in Traditional Chinese

Medicine for a few thousand years No Yes

 

History of large clinical use with a safe record Yes, in China hospitals

since 1995 with excellent safety record No No No Yes

 

pH and temperature stability Stable up to 65Ž in the pH range of 2-12.

Optimal pH is between 4-10 Stable up to 60Ž in the pH rang of 6-12

Unknown Unknown Active mainly between pH 4.5-9.8 range.

 

Heat sensitive Fibrinolytic strength in plasmin unit (CU) ~100 CU/g wet

weight ~40 CU/g wet weight Unknown Technically not a true fibrinolytic

enzyme Technically not a true fibrinolytic enzyme Enzyme in product is

standardized against Urokinase & t-PA Yes. Each mg of lumbrokinase

in Boluoke contains no less than 120,000u of tPA activity, and no less

than 100u of Urokinase activity No. But 1mg of nattokinase (95% pure

from cDNA source) contains ~12,000u of tPA activity (commercial

nattokinase is much weaker); and that 1mg wet weight Natto contains

~1.6u of Urokinase activity No. The ingredients in the imitation products

is likely just earthworm protein extract, or lumbrokinase of lower

enzymatic strength No. Technically not a true fibrinolytic enzyme No.

Usually standardized to milk clotting unit (MCU), or gelatin digestive unit

(GDU). Products on the market have quite variable enzymatic activities,

from 1000 to 500,000 MCU per gm

 

Dissolves fibrin directly Yes Yes Yes No evidence yet, only anecdotal

No, but indirectly by activating fibrinolysis Activates T-PA Yes Yes Yes

No evidence yet Yes

 

Decreases platelet aggregation Yes No evidence yet No evidence yet,

but likely No evidence yet Yes

 

Lower blood and plasma viscosity Yes Yes Yes No evidence yet No

evidence yet, but likely Evidence shows lumbrokinase supports the

inhibition of the intrinsic coagulation pathway and the activation of

fibrinolysis via an increase of t-PA activity. Lumbrokinase activates

plasminogen and hydrolyzes fibrin directly, reduces ESR, C-RP, TXB2,

and lowers blood viscosity and platelet aggregation function. FDP and

D-Dimer levels have been shown to increase sharply within three days

of Lumbrokinase administration. The rate at which Lumbrokinase lowers

plasma fibrinogen levels varies depending on the condition being

treated. Research results range from a 21% reduction in 12 weeks to a

33% reduction in 21 days. On average a reduction rate of 10 to 20% or

more in 4 weeks can be expected when patients are on the full dosage

of 2 capsules three times daily. Lumbrokinase will not reduce plasma

fibrinogen levels to below normal.

 

Instructions/How to Use: Product & Usage Information: Daily Use: 3-6

capsules Inactive Ingredients: Gelatin, polysaccharide. Initial Source:

Extracted from earthworm Contains No: Salicylates Contraindications:

Please consult a doctor before using this product. Take one four times

per day for one month to six weeks under direction of physician, then

one three times per day, with testing by your doctor.

 

1. How do you pronounce “Boluoke®”? Boluoke should be pronounced:

[bo-lo’-k]

 

2. How long before surgery should the patient stop taking

Boluoke®?The patient should stop Boluoke® 1 week prior to surgery,

and should be able to resume taking Boluoke® 15 days after surgery or

at the physician’s discretion.

 

3. Can lumbrokinase be safely used together with other blood thinners?

Lumbrokinase had been safely used together with blood thinners like

Aspirin, Heparin or Coumadin in various clinical studies, and does not

have adverse drug-drug interactions nor increase the chance of

bleeding other than what is inherent to the blood thinners. In a 1989

study Park et al. gave lumbrokinase to 10 normal volunteers, 10 DVT

patients on warfarin, and 5 patients with essential hypertension. No

change in PT, APTT was observed during the course of treatment, and

there was no hemorrhagic complication.

 

4. Is there any known drug interaction with lumbrokinase?

Lumbrokinase is not known to interact with any other medications at this

point. However, the latest research shows that lumbrokinase strongly

inhibits adhesion molecules on platelets. Thus it is advised that

lumbrokinase not be taken concurrently with other strong anti-platelet

medications like Plavix, Ticlid, etc.

 

5. Has there been any study comparing lumbrokinase with other anti-

platelet medicine? Lumbrokinase has been put head-to-head with

ticlopidine (Ticlid) in a clinical trial and the results showed that

lumbrokinase is as effective as ticlopidine in reducing symptoms and

improving EKG readings.(Zheng HJ, 2000)

 

6. Can Boluoke® be used on pregnant women? There is currently no

clinical study using lumbrokinase on pregnant women, even though

teratogenicity studies on animals showed no effect on pregnancy

weight, fetal growth, abortion rate, still birth rate, and fetal resorption

rate in mice compared to the placebo group. There was also no birth

defect detected. However, pregnant patients should only use Boluoke®

under physician’s approval and guidance.

 

7. How fast and how much can Boluoke® lower the patient’s plasma

fibrinogen level? The rate would vary depending on the condition being

treated and the starting fibrinogen level. Some studies showed a

reduction of 21% in 12 weeks, and some showed a reduction rate of

33% in 21 days. Most trials showed a reduction rate that is in between.

On average, a reduction rate of 10-20% (or more) in 4 weeks can be

expected when patients are on the full dosage of 2 capsules three times

daily. Boluoke® will not reduce plasma fibrinogen level to below normal.

 

8. What is lumbrokinase’s effect on FDP (Fibrin Degradation Product) or

D-Dimer? FDP and D-Dimer levels have been shown to increase

sharply within three days of lumbrokinase administration in healthy and

hyperfibrinosis individuals. Elevated FDP and D-Dimer levels indicate an

increased fibrinolysis activity.

 

9. Does Boluoke® affect ESR or C-RP? There are studies showing that

lumbrokinase can significantly decrease ESR, C-RP, and TXB2.

 

10. What are the contra-indications for taking Boluoke®? Contra-

indications for Boluoke® are: allergy to lumbrokinase or earthworm;

recent surgery, lumbar puncture, or arterial puncture; trauma;

aneurysm; active internal bleeding or GI ulceration; or any other

bleeding disorders.

 

11. Is Boluoke® effective in treating atherosclerosis? There is currently

no data on Boluoke®’s effect on atherosclerotic plaques. Because

arterial plaques consist of cholesterol, minerals, cells and other

substances beside fibrin, and Boluoke® may not be able to reduce them

on its own. Boluoke® is more likely to prevent plaque formation or re-

formation in combination with chelation treatment. There is, however,

evidence showing that lumbrokinase has a synergistic effect when

combined with antibiotics in the killing of bacteria with a protective bio-

film (e.g. nanobacteria, pseudomonas). Even though it is still

controversial, some researchers believe that nanobacteria play a central

role in the atherosclerotic process

 

12. Can Boluoke® be combined with other enzyme products? There is a

theoretical possibility that Boluoke® may be cleaved and rendered

ineffective by other enzymes, so we currently do not recommend dosing

Boluoke® with another enzyme product. If you do have to take other

enzyme products while on Boluoke®, try to space more time between

the dosing of the two enzyme products (i.e. at least 2 hours).

 

13. How is Boluoke® different from other products that contain

lumbrokinase? Boluoke® has been through all phases of clinical trials in

China. All other lumbrokinase products currently on the market often are

citing Boluoke’s® credential and research, and are not disclosing the

enzymatic strength of their lumbrokinase (Boluoke’s® enzymatic

strength is standardized against Urokinase and t-PA activities). So be

careful not to fall for second grade imitation products! (Go to What’s

New for more info)

 

14. What is the suggested protocol for taking Boluoke®?” If Boluoke® is

to be taken for chronic conditions, it should be taken at the dose of 1

capsule one to three times daily 30 minutes before the meal. However,

the practitioner may recommend 2 capsules three times daily for 3 to 6

weeks in conditions with severe hypoperfusion.”

 

 

Best regards,

 

 

Tel: (H): +353-(0) or (M): +353-(0)

 

 

 

 

Ireland.

Tel: (W): +353-(0) or (M): +353-(0)

 

 

 

" Man who says it can't be done should not interrupt man doing it " -

Chinese Proverb